Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy
Glossary on
off
Printer Friendly Page Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

Clinicaltrials.gov identifier:
NCT04455750


Treatment study for men with metastatic prostate cancer

Study Contact Information:

For additional information, please contact:
Arpit Rao, MD 713-798-4508 [email protected]

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

About this Study

This study is testing the effectiveness of adding a type of known as a to androgen-deprivation therapy for men with prostate cancer that has become resistant to standard . NOTE: This study is no longer enrolling people. 

 

This Study is Open To:

NOTE: This study is no longer enrolling people. 

 

This Study is Not Open To:

NOTE: This study is no longer enrolling people.